Endobronchial Valve Therapy
Minimally invasive bronchoscopic approach for severe COPD / Emphysema
Endobronchial valve therapy places small one-way valves into the damaged portion of the lung, causing that section to deflate. This allows healthy lung tissue to expand more fully, making breathing easier. No incisions are made.
Who Is a Candidate?
Suitable Candidates
- ✓ GOLD Stage 3-4 emphysema
- ✓ Heterogeneous emphysema distribution (confirmed by HRCT)
- ✓ FEV1 between 15-45%
- ✓ Complete interlobar fissure (≥90% integrity)
- ✓ Former smoker (at least 4 months smoke-free)
- ✓ Persistent breathlessness despite maximal medical therapy
Not Eligible
- ✗ Active smoking
- ✗ COPD exacerbation in the last 6 months
- ✗ Pulmonary hypertension (severe)
- ✗ Bullous emphysema (large bullae)
- ✗ FEV1 below 15%
| Condition | For Valve | For Coil |
|---|---|---|
| Collateral Ventilation | Absolute Barrier | Not a barrier |
| Homogeneous Emphysema | Usually not suitable | May be suitable |
| DLCO < 20% | High Risk / Contraindicated | High Risk / Contraindicated |
| Fissure Integrity | Must be complete | Not important |
How the Procedure Works
| Feature | Coil (Spring) | Valve (Flap) |
|---|---|---|
| Mechanism | Parenchymal Compression (Tension) | Airway Blockade (Plug) |
| Units per Lobe | Fixed Target (~10) | Anatomical Requirement (3-5) |
| Incomplete Placement | May provide partial benefit | Generally results in failure |
Benefits & Expected Outcomes
- Minimally invasive procedure — no incisions
- Average +25-40 meter improvement in 6-minute walk distance
- Significant improvement in dyspnea (mMRC scale)
- Valves can be removed if needed (reversible)
- Average 15-20% increase in FEV1 and marked reduction in residual volume (RV)
- Long-term efficacy proven (LIBERATE, EMPROVE trials)
Risks & Complications
⚠️ As with any medical procedure, there are risks. The following is evidence-based information.
- • Pneumothorax (10-15% — most common complication)
- • COPD exacerbation (20%)
- • Valve migration (5%)
- • Hemoptysis (rare)
- • Pneumonia (rare)
IMPORTANT NOTE — Timing: Most pneumothorax events occur within the first 48-72 hours, which is why patients must be kept under in-hospital observation during this period. This is critical for patient safety and clinical management.
Recovery Process
Tests Required for Evaluation
Upload the following documents in your Free Evaluation form for remote candidacy assessment:
- ✓ High-Resolution Chest CT (≤1mm slice, non-contrast, within 1 month, on CD)
- ✓ Spirometry + DLCO (within 1 month)
- ✓ 6-Minute Walk Test
- ✓ Arterial Blood Gas Analysis
- ✓ Echocardiogram (to rule out pulmonary hypertension)
- ✓ Complete blood count + biochemistry
- ✓ Current medication list
Compare Your Options
| Feature | Bronchoscopic (Valve) | Bronchoscopic (coil) | Surgical LVRS |
|---|---|---|---|
| Invasiveness | Minimal | Minimal | High |
| Recovery | 2-4 weeks | 3-6 weeks | 6-12 weeks |
| Ideal Emphysema Type | Heterogeneous | Homogeneous/Heterogeneous | Advanced Heterogeneous |
| Reversible | Yes | Partial | No |
Patient Experience
Three months after the procedure, I can walk 350–400 m farther. I can finally take walks in the park with my grandchild.
Frequently Asked Questions
Scientific References
Got a question before deciding?
Our coordinator is on WhatsApp, ready to help.
Next Treatment
Endobronchial Coil Treatment
Spiral coil implantation for homogeneous and heterogeneous emphysema
